% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Chen:153077,
      author       = {C. Chen and H. Dorado Garcia and M. Scheer and A. G.
                      Henssen$^*$},
      title        = {{C}urrent and {F}uture {T}reatment {S}trategies for
                      {R}habdomyosarcoma.},
      journal      = {Frontiers in oncology},
      volume       = {9},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2020-00159},
      pages        = {1458},
      year         = {2019},
      abstract     = {Rhabdomyosarcoma (RMS) is the most common soft tissue
                      sarcoma in children, and can be subcategorized
                      histologically and/or based on PAX-FOXO1 fusion gene status.
                      Over the last four decades, there have been no significant
                      improvements in clinical outcomes for advanced and
                      metastatic RMS patients, underscoring a need for new
                      treatment options for these groups. Despite significant
                      advancements in our understanding of the genomic landscape
                      and underlying biological mechanisms governing RMS that have
                      informed the identification of novel therapeutic targets,
                      development of these therapies in clinical trials has lagged
                      far behind. In this review, we summarize the current
                      frontline multi-modality therapy for RMS according to
                      pediatric protocols, highlight emerging targeted therapies
                      and immunotherapies identified by preclinical studies, and
                      discuss early clinical trial data and the implications they
                      hold for future clinical development.},
      subtyp        = {Review Article},
      cin          = {L201},
      ddc          = {610},
      cid          = {I:(DE-He78)L201-20160331},
      pnm          = {899 - ohne Topic (POF3-899)},
      pid          = {G:(DE-HGF)POF3-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31921698},
      pmc          = {pmc:PMC6933601},
      doi          = {10.3389/fonc.2019.01458},
      url          = {https://inrepo02.dkfz.de/record/153077},
}